Xalkori - direct healthcare professional communication (DHPC)

crizotinib

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Xalkori (crizotinib): Vision disorders, including risk of severe visual loss, need for monitoring in paediatric patients

Key facts

• Medicine name:
  Xalkori
• Active substance:
  crizotinib
• Therapeutic area (MeSH):
  Carcinoma, Non-Small-Cell Lung
• Procedure number:
  EMEA/H/C/002489/II/0072
• Regulatory outcome:
  Variation
• DHPC type:
  Adverse event
• Human ATC codes:
  L01ED01